[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 25 of about 25
1. Velázquez D, de Pablo P, García D, Ramírez JR: Primary cutaneous marginal zone B-cell lymphoma: An atypical case. Dermatol Online J; 2010;16(12):5
Hazardous Substances Data Bank. CHLORAMBUCIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous marginal zone B-cell lymphoma: An atypical case.
  • Primary cutaneous marginal zone B-cell lymphoma (PCMZBCL) is an entity with an indolent behavior, which clinically appears as erythematous papules, nodules, or plaques, solitary or multiple, on the trunk or upper extremities.
  • It has been associated with autoimmune diseases and infections.
  • We present the case of a 77-year-old woman with an atypical PCMZBCL with extracutaneous spread and associated autoimmune hemolytic anemia.
  • [MeSH-major] Lymphoma, B-Cell, Marginal Zone / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Aged. Anemia, Hemolytic, Autoimmune / complications. Anemia, Hemolytic, Autoimmune / drug therapy. Antibodies, Monoclonal, Murine-Derived / therapeutic use. Antigens, CD / analysis. Antineoplastic Agents, Alkylating / therapeutic use. B-Lymphocytes / pathology. Chlorambucil / therapeutic use. Erythema / etiology. Female. Humans. Rituximab. Telangiectasis / etiology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21199631.001).
  • [ISSN] 1087-2108
  • [Journal-full-title] Dermatology online journal
  • [ISO-abbreviation] Dermatol. Online J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD; 0 / Antineoplastic Agents, Alkylating; 18D0SL7309 / Chlorambucil; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


2. Zhang HY, Liu AL, Zhou LS, He MX, Wang JX: Primary cutaneous marginal zone B-cell lymphoma with amyloid deposition: report of two cases with review of literature. Chin J Cancer; 2010 Jun;29(6):634-40
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous marginal zone B-cell lymphoma with amyloid deposition: report of two cases with review of literature.
  • If there was a great amount of amyloid depositions in the skin tissue, it would be considered to be amyloid deposition disease at first, and then primary cutaneous marginal zone B-cell lymphoma (PCMZL).
  • This study was to analyze the diagnosis and differential diagnosis of two cases of PCMZL with amyloid deposition.
  • Three years after the initial diagnosis, he developed recurrences on the right para-auxillary that was still diagnosed with "probably amyloidosis".
  • Four years after the first diagnosis, the patient presented a lesion on the right para-auxillary with a diameter of 2 cm and a lesion on the temporal-parietal dural with a size of 6.0 cmx3.0 cmx3.0 cm.
  • Case 2, a 68-year-old Chinese male, had a subcutaneous mass next to back of the left ear with a size of 9.0 cmx5.0 cm, and he underwent a operation one year previously because of subcutaneous mass in the same site.
  • Microscopically, the tumors of both cases were located in dermis and subcutaneous, tumor cells were medium size with a nodular or diffuse distribution, and some of tumor cells were plasmacytoid/plasma cells.
  • Reactive lymphoid follicles with germinal centers and foreign body giant cells in the stroma were found surrounding the amyloid deposits.
  • Congo red staining showed positive of amyloid deposition in tumor tissues of both cases.
  • CONCLUSIONS: Our findings suggest that amyloid deposition rarely present in both primary and metastatic tumors in PCMZL, and its diagnosis should be considered to avoid misdiagnosis.
  • The patients with PCMZL should undergo regular examinations and chemotherapy as well as a long-term follow-up since it is apt to recur or relapse.
  • [MeSH-major] Amyloidosis / pathology. Head and Neck Neoplasms / pathology. Lymphoma, B-Cell, Marginal Zone / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Antigens, CD / metabolism. Antigens, CD45 / metabolism. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / therapeutic use. Diagnosis, Differential. Doxorubicin / therapeutic use. Elbow. Follow-Up Studies. Humans. Interferon Regulatory Factors / metabolism. Magnetic Resonance Imaging. Male. Neoplasm Recurrence, Local. Prednisone / therapeutic use. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20507739.001).
  • [ISSN] 1000-467X
  • [Journal-full-title] Chinese journal of cancer
  • [ISO-abbreviation] Chin J Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Interferon Regulatory Factors; 0 / interferon regulatory factor-4; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; EC 3.1.3.48 / Antigens, CD45; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


3. Breton AL, Poulalhon N, Balme B, Thomas L, Dalle S: Primary cutaneous marginal zone lymphoma as a complication of radiation therapy: Case report and review. Dermatol Online J; 2010;16(12):6
Hazardous Substances Data Bank. CHLORAMBUCIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous marginal zone lymphoma as a complication of radiation therapy: Case report and review.
  • BACKGROUND: The occurrence of primary cutaneous B-cell lymphoma at the site of radiation therapy is exceptional.
  • We report herein the case of a primary cutaneous marginal zone lymphoma arising at the site of radiotherapy for breast cancer.
  • METHODS/RESULTS: A seventy-year-old woman was diagnosed in 2005 with an invasive ductal carcinoma of the left breast, which was treated with surgery, adjuvant chemotherapy, and radiation therapy.
  • Three years later she developed several cutaneous nodules on her left breast, followed by similar lesions on her back.
  • Histologic, immunohistochemistry, and molecular findings were consistent with the diagnosis of cutaneous marginal zone lymphoma.
  • CONCLUSIONS: To our knowledge, this is the first published case of primary cutaneous marginal zone lymphoma occurring at the site of radiotherapy.
  • Cutaneous surveillance is proposed from the first year after irradiation in order to detect new primary malignancies, including this rare cutaneous neoplasm.
  • [MeSH-major] Lymphoma, B-Cell, Marginal Zone / etiology. Neoplasms, Radiation-Induced / etiology. Neoplasms, Second Primary / etiology. Radiotherapy, Adjuvant / adverse effects. Skin Neoplasms / etiology
  • [MeSH-minor] Aged. Antibodies, Monoclonal, Murine-Derived / administration & dosage. Antineoplastic Agents, Hormonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Breast Neoplasms / radiotherapy. Breast Neoplasms / surgery. Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Ductal, Breast / radiotherapy. Carcinoma, Ductal, Breast / surgery. Chlorambucil / administration & dosage. Combined Modality Therapy. Female. Humans. Rituximab

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21199632.001).
  • [ISSN] 1087-2108
  • [Journal-full-title] Dermatology online journal
  • [ISO-abbreviation] Dermatol. Online J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents, Hormonal; 18D0SL7309 / Chlorambucil; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


Advertisement
4. Senff NJ, Noordijk EM, Kim YH, Bagot M, Berti E, Cerroni L, Dummer R, Duvic M, Hoppe RT, Pimpinelli N, Rosen ST, Vermeer MH, Whittaker S, Willemze R, European Organization for Research and Treatment of Cancer, International Society for Cutaneous Lymphoma: European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. Blood; 2008 Sep 1;112(5):1600-9
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas.
  • Primary cutaneous B-cell lymphomas (CBCL) represent approximately 20% to 25% of all primary cutaneous lymphomas.
  • With the advent of the World Health Organization-European Organization for Research and Treatment of Cancer (EORTC) Consensus Classification for Cutaneous Lymphomas in 2005, uniform terminology and classification for this rare group of neoplasms were introduced.
  • However, staging procedures and treatment strategies still vary between different cutaneous lymphoma centers, which may be because consensus recommendations for the management of CBCL have never been published.
  • Based on an extensive literature search and discussions within the EORTC Cutaneous Lymphoma Group and the International Society for Cutaneous Lymphomas, the present report aims to provide uniform recommendations for the management of the 3 main groups of CBCL.
  • Despite these limitations, there was consensus among the members of the multidisciplinary expert panel that these recommendations reflect the state-of-the-art management as currently practiced in major cutaneous lymphoma centers.
  • They may therefore contribute to uniform staging and treatment and form the basis for future clinical trials in patients with a CBCL.
  • [MeSH-major] Lymphoma, B-Cell / therapy. Skin Neoplasms / therapy
  • [MeSH-minor] Anti-Bacterial Agents / therapeutic use. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Agents / therapeutic use. Humans. Interferon Type I / administration & dosage. Lyme Disease / complications. Lyme Disease / drug therapy. Lymphoma, B-Cell, Marginal Zone / diagnosis. Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, B-Cell, Marginal Zone / therapy. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / therapy. Neoplasm Staging / methods. Radiotherapy Dosage. Recombinant Proteins. Rituximab

  • Genetic Alliance. consumer health - Cutaneous B-Cell Lymphomas.
  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18567836.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Practice Guideline; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / Interferon Type I; 0 / Recombinant Proteins; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 123
  •  go-up   go-down


5. Cozzio A, Kempf W, Schmid-Meyer R, Gilliet M, Michaelis S, Schärer L, Burg G, Dummer R: Intra-lesional low-dose interferon alpha2a therapy for primary cutaneous marginal zone B-cell lymphoma. Leuk Lymphoma; 2006 May;47(5):865-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intra-lesional low-dose interferon alpha2a therapy for primary cutaneous marginal zone B-cell lymphoma.
  • Primary cutaneous marginal zone lymphomas (pcMZL) belong to the primary cutaneous B-cell lymphoma (pCBCL) group.
  • They are characterized by their restriction to the skin and a high likelihood of recurrence after various treatment modalities.
  • First-line therapy consists of surgery and radiotherapy.
  • These therapies may not always be indicated in young patients or in patients with pCBCL located in the face, where surgery or radiotherapy may leave disfiguring scars or radioderma.
  • Eight patients with pcMZL were treated with intra-lesional injections of 3 million units of recombinant IFNalpha2a three times per week.
  • Two patients relapsed 4 and 12 months after treatment, respectively, but tumor regression was repeated after additional cycles of intra-lesional IFNalpha2a.
  • Thus, intra-lesional IFNalpha2a may represent a valuable alternative to surgery and radiotherapy as first-line treatment of pcMZL.
  • [MeSH-major] Interferon-alpha / administration & dosage. Lymphoma, B-Cell, Marginal Zone / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16753871.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Interferon-alpha; 0 / Recombinant Proteins; 76543-88-9 / interferon alfa-2a
  •  go-up   go-down


6. Park MY, Jung HJ, Park JE, Kim YC: Pediatric primary cutaneous marginal zone B-cell lymphoma treated with intralesional rituximab. Eur J Dermatol; 2010 Jul-Aug;20(4):533-4
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric primary cutaneous marginal zone B-cell lymphoma treated with intralesional rituximab.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Lymphoma, B-Cell / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20542839.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


7. Rosmaninho A, Alves R, Lima M, Lobo I, Amorim I, Selores M: Red nose: primary cutaneous marginal zone B-cell lymphoma. Leuk Res; 2010 May;34(5):682-4
Hazardous Substances Data Bank. METRONIDAZOLE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Red nose: primary cutaneous marginal zone B-cell lymphoma.
  • [MeSH-major] Lymphoma, B-Cell, Marginal Zone / pathology. Nose / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Administration, Topical. Aged, 80 and over. Anti-Bacterial Agents / therapeutic use. Anti-Infective Agents / therapeutic use. Antineoplastic Agents / administration & dosage. Female. Humans. Immunohistochemistry. Interferon-gamma / administration & dosage. Metronidazole / therapeutic use. Minocycline / therapeutic use. Recombinant Proteins. Rosacea / complications. Rosacea / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. MINOCYCLINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19945162.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Anti-Infective Agents; 0 / Antineoplastic Agents; 0 / Recombinant Proteins; 140QMO216E / Metronidazole; 82115-62-6 / Interferon-gamma; FYY3R43WGO / Minocycline
  •  go-up   go-down


8. Bohn-Sarmiento U, Aguiar-Bujanda D, Aguiar-Morales J, Cabrera-Suárez MA: Primary cutaneous marginal zone B-cell lymphoma (PCMZL-MALT). Clin Transl Oncol; 2006 Jul;8(7):542-3
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous marginal zone B-cell lymphoma (PCMZL-MALT).
  • [MeSH-major] Lymphoma, B-Cell, Marginal Zone / drug therapy. Skin Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2001 Aug 15;19(16):3602-10 [11504742.001]
  • [Cites] J Clin Oncol. 1996 Feb;14(2):549-55 [8636770.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):398-405 [11208831.001]
  • [Cites] J Cutan Pathol. 1997 Sep;24(8):457-61 [9331890.001]
  • [Cites] Dermatology. 1994;189 Suppl 2:8-15 [7841565.001]
  • [Cites] J Clin Oncol. 2000 May;18(10):2152-68 [10811681.001]
  • [Cites] J Am Acad Dermatol. 1991 Apr;24(4):584-90 [2033136.001]
  • [Cites] Blood. 1997 Jul 1;90(1):354-71 [9207472.001]
  • [Cites] Blood. 2002 Feb 1;99(3):800-5 [11806979.001]
  • [Cites] Arch Dermatol. 2005 Sep;141(9):1139-45 [16172311.001]
  • (PMID = 16870546.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Italy
  •  go-up   go-down


9. Bachmeyer C, Orlandini V, Aractingi S: Topical mechlorethamine and clobetasol in multifocal primary cutaneous marginal zone-B cell lymphoma. Br J Dermatol; 2006 Jun;154(6):1207-9
Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical mechlorethamine and clobetasol in multifocal primary cutaneous marginal zone-B cell lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / drug therapy. Lymphoma, Non-Hodgkin / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. Clobetasol .
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16704661.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 50D9XSG0VR / Mechlorethamine; ADN79D536H / Clobetasol
  •  go-up   go-down


10. Willemze R: Primary cutaneous B-cell lymphoma: classification and treatment. Curr Opin Oncol; 2006 Sep;18(5):425-31
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous B-cell lymphoma: classification and treatment.
  • PURPOSE OF REVIEW: There has been confusion and debate regarding the definition, terminology, and optimal treatment of the different types of primary cutaneous B-cell lymphomas.
  • This review presents the new World Health Organization-European Organization for the Research and Treatment of Cancer classification for cutaneous lymphomas; describes clinicopathologic, immunophenotypic, and genetic features of the different types of cutaneous B-cell lymphomas in this classification; and discusses current views on treatment of these lymphomas.
  • RECENT FINDINGS: The three main types of cutaneous B-cell lymphomas in this new classification are primary cutaneous marginal zone B-cell lymphoma, primary cutaneous follicle center lymphoma, and primary cutaneous large B-cell lymphoma (leg type).
  • Primary cutaneous marginal zone B-cell and primary cutaneous follicle center lymphoma are indolent types with an excellent prognosis that should be treated primarily with nonaggressive therapies.
  • Primary cutaneous large B-cell lymphoma (leg type) is an aggressive lymphoma that should be treated primarily with aggressive chemotherapy.
  • SUMMARY: The World Health Organization-European Organization for the Research and Treatment of Cancer classification will contribute to uniform diagnosis, management, and treatment of patients with cutaneous B-cell lymphoma and will prevent patients with indolent types of the disease from being treated inappropriately with systemic chemotherapy.
  • [MeSH-major] Lymphoma, B-Cell / classification. Lymphoma, B-Cell / therapy. Skin Neoplasms / classification. Skin Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16894288.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 58
  •  go-up   go-down


11. Ingen-Housz-Oro S, Bagot M: [Cutaneous lymphomas]. Rev Prat; 2009 Nov 20;59(9):1207-15
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cutaneous lymphomas].
  • Cutaneous lymphomas are lymphoproliferations affecting skin only at the time of diagnosis.
  • There are two major types, B-cell lymphomas and T-cell lymphomas, which prognosis depends of histological subtype and staging evaluation.
  • In cutaneous B-cell lymphomas, there are two indolent subtypes (primary cutaneous marginal zone B-cell lymphoma and primary cutaneous follicle center lymphoma) and one more aggressive type (primary cutaneous diffuse large B-cell lymphoma, leg type).
  • Classification of T-cell lymphomas distinguishes indolent subtypes such as mycosis fungoides, the most frequent of T-cell lymphomas, and CD30+ lymphoproliferations such as lymphomatoid papulosis, whereas other T-cell lymphoma subtypes have a more pejorative prognosis such as Sezary syndrome (erythrodermic and leukemic form of mycosis fungoides) and CD30- lymphomas.
  • Staging evaluation with CT-scan of chest, abdomen and pelvis, bone marrow examination if necessary and lymph node biopsy if palpable node over 1 or 1.5 cm diameter, is necessary for therapeutic decision.
  • [MeSH-major] Lymphoma. Skin Neoplasms
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Humans. Immunohistochemistry. Lymphoma, B-Cell / diagnosis. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell / radiography. Lymphoma, B-Cell / radiotherapy. Lymphoma, B-Cell / surgery. Lymphoma, T-Cell / diagnosis. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / pathology. Lymphoma, T-Cell / radiography. Lymphoma, T-Cell / radiotherapy. Lymphoma, T-Cell / surgery. Mycosis Fungoides / diagnosis. Mycosis Fungoides / radiography. Neoplasm Staging. Prognosis. Radiography, Abdominal. Radiography, Thoracic. Sezary Syndrome / diagnosis. Sezary Syndrome / pathology. Sezary Syndrome / radiography. Skin / pathology. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19961071.001).
  • [ISSN] 0035-2640
  • [Journal-full-title] La Revue du praticien
  • [ISO-abbreviation] Rev Prat
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 16
  •  go-up   go-down


12. Valencak J, Weihsengruber F, Rappersberger K, Trautinger F, Chott A, Streubel B, Muellauer L, Der-Petrossian M, Jonak C, Binder M, Raderer M: Rituximab monotherapy for primary cutaneous B-cell lymphoma: response and follow-up in 16 patients. Ann Oncol; 2009 Feb;20(2):326-30
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rituximab monotherapy for primary cutaneous B-cell lymphoma: response and follow-up in 16 patients.
  • BACKGROUND: We have carried out a retrospective analysis to evaluate the therapeutic value of the anti-CD20 antibody rituximab in 16 consecutive patients with primary cutaneous CD20+ B-cell lymphomas.
  • PATIENTS AND METHODS: Sixteen patients (4 females, 12 males) with a median age of 54 years received systemic therapy with rituximab 375 mg/m(2) once weekly for four or six consecutive weeks.
  • Eleven patients had primary cutaneous follicle center cell lymphoma and five patients had a primary cutaneous marginal zone B-cell lymphoma.
  • CONCLUSIONS: On the basis of our results, single-agent treatment with i.v. rituximab appears to be feasible and safe and results in a high rate of durable remissions.
  • Judging from our data, it appears to be an attractive treatment option and should be directly compared with local radiotherapy.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18836086.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Immunologic Factors; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


13. Pedraz J, Delgado Y, Aragüés M, Fraga J, García-Díez A, Fernández-Herrera J: [Cutaneous marginal zone B-cell lymphoma treated with rituximab]. Actas Dermosifiliogr; 2005 Nov;96(9):593-7
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cutaneous marginal zone B-cell lymphoma treated with rituximab].
  • [Transliterated title] Linfoma cutáneo de células B de la zona marginal tratado con rituximab.
  • Marginal zone B-cell lymphoma (MZL) is probably the most frequent of the primary cutaneous B-cell lymphomas, which are entities with indolent behavior.
  • The prognosis is excellent despite frequent cutaneous recurrences.
  • We present the case of a 40-year-old male who, after having several recurrences of MZL over a ten-year period, was treated with rituximab for multiple skin lesions.
  • The patient showed full remission after four weeks of treatment, and developed cytokine-release syndrome after the first infusion of the drug.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Lymphoma, B-Cell / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16476304.001).
  • [ISSN] 0001-7310
  • [Journal-full-title] Actas dermo-sifiliográficas
  • [ISO-abbreviation] Actas Dermosifiliogr
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


14. Kyrtsonis MC, Siakantaris MP, Kalpadakis C, Dimopoulou MN, Vassilakopoulos TP, Kontopidou FN, Antoniou C, Korkolopoulou P, Panayiotidis P, Pangalis GA: Favorable outcome of primary cutaneous marginal zone lymphoma treated with intralesional rituximab. Eur J Haematol; 2006 Oct;77(4):300-3
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Favorable outcome of primary cutaneous marginal zone lymphoma treated with intralesional rituximab.
  • Primary cutaneous marginal zone lymphoma (PCMZL) is an indolent disease.
  • Treatment options include excision, local irradiation, interferon-alpha or chemotherapy.
  • We present two patients with PCMZL and multiple skin lesions successfully treated with intralesional administration of the anti-CD20 monoclonal antibody rituximab.
  • The first presented with four red skin lesions and the second with two.
  • Biopsy of the largest lesion revealed marginal zone B-cell lymphoma in both patients.
  • Skin lesions gradually regressed.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Lymphoma / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Aged. Antibodies, Monoclonal, Murine-Derived. Female. Humans. Injections, Intralesional. Rituximab. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16856917.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


15. Roggero E, Zucca E, Mainetti C, Bertoni F, Valsangiacomo C, Pedrinis E, Borisch B, Piffaretti JC, Cavalli F, Isaacson PG: Eradication of Borrelia burgdorferi infection in primary marginal zone B-cell lymphoma of the skin. Hum Pathol; 2000 Feb;31(2):263-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Eradication of Borrelia burgdorferi infection in primary marginal zone B-cell lymphoma of the skin.
  • Primary cutaneous B-cell lymphomas have been associated with Borrelia burgdorferi, the spirochete responsible for Lyme disease.
  • Recently, cutaneous marginal zone B-cell lymphoma has been proposed as a distinct clinical-pathological entity.
  • We report a case of primary cutaneous marginal zone lymphoma, associated with B burgdorferi infection.
  • Polymerase chain reaction (PCR) amplification of the third complementarity determining region (CDR3) of the immunoglobulin heavy chain gene showed the presence of a monoclonal lymphoproliferation, therefore strengthening the histological diagnosis of a malignant process.
  • B burgdorfer-specific hbb gene sequences were detected by PCR in the lymphoma tissue at diagnosis but not after antibiotic treatment.
  • A nearly complete clinical and histological regression was observed after B burgdorferi eradication, with immunohistochemistry studies showing disappearance of plasma cell differentiation and a marked decline in the number of CD3+ T cells and Ki-67+ cells.
  • Our case confirms the link between B burgdorferi and some cutaneous lymphomas.
  • The disappearance of the microorganism accompanied by the unequivocal decrease of most indicators of active T- and B-cell immune response strongly supported a pathogenetic role for B burgdorferi in sustaining an antigen-driven development and growth of this cutaneous marginal zone lymphoma.
  • Antibiotic therapy (analogous to Helicobacter pylori infection in gastric MALT lymphoma) might be helpful with the aim of averting or at least deferring the indication for more aggressive treatment.
  • [MeSH-major] Lyme Disease / drug therapy. Lymphoma, B-Cell / microbiology. Skin Neoplasms / microbiology
  • [MeSH-minor] Aged. Anti-Bacterial Agents / therapeutic use. Borrelia burgdorferi Group / genetics. DNA, Bacterial / analysis. Humans. Immunoglobulin Heavy Chains / genetics. Male. Polymerase Chain Reaction. Sequence Analysis, DNA

  • MedlinePlus Health Information. consumer health - Lyme Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10685647.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / DNA, Bacterial; 0 / Immunoglobulin Heavy Chains
  •  go-up   go-down


16. Morales AV, Advani R, Horwitz SM, Riaz N, Reddy S, Hoppe RT, Kim YH: Indolent primary cutaneous B-cell lymphoma: experience using systemic rituximab. J Am Acad Dermatol; 2008 Dec;59(6):953-7
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Indolent primary cutaneous B-cell lymphoma: experience using systemic rituximab.
  • BACKGROUND: Optimal treatment of indolent primary cutaneous B-cell lymphoma (CBCL), marginal zone lymphoma, and follicle center lymphoma, presenting as multiple lesions, has yet to be established.
  • OBJECTIVE: We sought to assess the efficacy of systemic rituximab in the treatment of CBCL.
  • The efficacy end points included were objective response rate, time to response, time to progression, and duration of response.
  • RESULTS: Ten patients with follicle center lymphoma and 5 with marginal zone lymphoma were included.
  • All patients with follicle center lymphoma had a response with 80% achieving complete response.
  • Of the patients with marginal zone lymphoma, 3 had a response, one stable disease, and one progressive disease.
  • Median time to response, duration of response, and time to progression was 30 days, 24 months, and 24 months, respectively.
  • CONCLUSIONS: This study, although small, suggests that rituximab is a reasonable first-line treatment option for indolent CBCL with multiple lesions where local treatment is not effective or desirable.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Lymphoma, B-Cell / drug therapy. Skin Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Indolent B cell lymphoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18817999.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


17. Zinzani PL, Quaglino P, Pimpinelli N, Berti E, Baliva G, Rupoli S, Martelli M, Alaibac M, Borroni G, Chimenti S, Alterini R, Alinari L, Fierro MT, Cappello N, Pileri A, Soligo D, Paulli M, Pileri S, Santucci M, Bernengo MG, Italian Study Group for Cutaneous Lymphomas: Prognostic factors in primary cutaneous B-cell lymphoma: the Italian Study Group for Cutaneous Lymphomas. J Clin Oncol; 2006 Mar 20;24(9):1376-82
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in primary cutaneous B-cell lymphoma: the Italian Study Group for Cutaneous Lymphomas.
  • PURPOSE: Primary cutaneous B-cell lymphomas (PCBCLs) are a distinct group of primary cutaneous lymphomas with few and conflicting data on their prognostic factors.
  • PATIENTS AND METHODS: The study group included 467 patients with PCBCL who were referred, treated, and observed in 11 Italian centers (the Italian Study Group for Cutaneous Lymphomas) during a 24-year period (1980 to 2003).
  • All of the patients were reclassified according to the WHO-European Organisation for Research and Treatment of Cancer (EORTC) classification.
  • RESULTS: Follicle center lymphoma (FCL) accounted for 56.7% of occurrences, followed by marginal-zone B-cell lymphoma (MZL; 31.4%); diffuse large B-cell lymphoma (DLBCL), leg type, was reported in 10.9% of patients.
  • Radiotherapy was the first-line treatment in 52.5% of patients and chemotherapy was the first-line treatment in 24.8% of patients.
  • Compared with FCL/MZL, DLBCL, leg type, was characterized by statistically significant lower complete response rates, higher incidence of multiple cutaneous relapses and extracutaneous spreading, shorter time to progression, and shorter OS rates.
  • The only variable with independent prognostic significance on the OS was the clinicopathologic diagnosis according to the WHO-EORTC classification (DLBCL, leg-type, showed a significantly worse prognosis v FCL and MZL; P < .001), whereas the only variable with independent prognostic significance on disease-free survival was the presence of a single cutaneous lesion (P = .001).
  • CONCLUSION: Our study identifies a possible PCBCL subclassification and the extent of cutaneous involvement as the two most relevant prognostic factors in PCBCL.
  • [MeSH-major] Lymphoma, B-Cell / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Cutaneous B-Cell Lymphomas.
  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2006 Aug 20;24(24):4041; author reply 4041-2 [16921065.001]
  • (PMID = 16492713.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


18. Chen YF, Li YC, Chen LM, Tu CC, Chang CC, Kuo SY, Lin SH, Chuang SS: Primary cutaneous diffuse large B cell lymphoma relapsed solely as a huge lung tumor mimicking a primary pulmonary lymphoma. Int J Hematol; 2010 Jan;91(1):112-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous diffuse large B cell lymphoma relapsed solely as a huge lung tumor mimicking a primary pulmonary lymphoma.
  • Primary cutaneous large B cell lymphoma, leg type (PCLBCL-leg) has recently been identified and recognized as a specific entity.
  • Patients with PCLBCL-leg have a higher relapse rate and a poorer prognosis than the other types of primary cutaneous B cell lymphomas, and disease relapse is confined to the skin in the majority of cases with rare exclusive extracutaneous progression.
  • The late occurrence of lymphoma in patients with a prior history of lymphoma may represent a relapse/progression or a distinct tumor unrelated to the original one.
  • The distinction is of important clinical and therapeutic implications.
  • Here, we report the case of a 90-year-old lady with a history of PCLBCL-leg in complete remission after radiotherapy that developed a huge, solitary pulmonary lymphoma without lymphadenopathy 14 months later.
  • The latter was initially considered as stage IE primary pulmonary lymphoma and was treated with combination chemotherapy resulting in complete remission.
  • Retrospective pathologic review and B cell clonality study revealed that the pulmonary tumor was a diffuse large B cell lymphoma of the same clonal origin as the PCLBCL-leg.
  • This case is unique in the exclusive pulmonary relapse and illustrates the importance of expert pathological review and molecular study in the management of lymphoma patients with unusual clinical features.
  • [MeSH-major] Lung Neoplasms / pathology. Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged, 80 and over. Biopsy. Clone Cells / pathology. Diagnosis, Differential. Fatal Outcome. Female. Humans. Neoplasm Recurrence, Local. Radiography

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2004 Jan 1;103(1):275-82 [14504078.001]
  • [Cites] J Clin Oncol. 2001 Aug 15;19(16):3602-10 [11504742.001]
  • [Cites] Arch Pathol Lab Med. 2010 Jul;134(7):996-1002 [20586627.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2009 Jan;17(1):77-81 [19115486.001]
  • [Cites] Ann Hematol. 2009 Sep;88(9):839-46 [19139892.001]
  • [Cites] Br J Haematol. 2002 Sep;118(3):809-12 [12181049.001]
  • [Cites] Cancer. 1972 Jan;29(1):252-60 [5007387.001]
  • [Cites] Blood. 2005 May 15;105(10):3768-85 [15692063.001]
  • [Cites] Curr Opin Oncol. 2006 Sep;18(5):425-31 [16894288.001]
  • [Cites] Leuk Lymphoma. 2003 Jan;44(1):117-21 [12691150.001]
  • [Cites] Radiat Med. 2000 Nov-Dec;18(6):369-75 [11153690.001]
  • [Cites] Am J Surg Pathol. 2002 Jan;26(1):76-81 [11756772.001]
  • [Cites] Cancer. 1996 Feb 15;77(4):757-62 [8616769.001]
  • [Cites] Jpn J Clin Oncol. 2004 Sep;34(9):510-4 [15466823.001]
  • [Cites] Leuk Lymphoma. 2004 Aug;45(8):1539-43 [15370204.001]
  • [Cites] J Clin Oncol. 2006 Mar 20;24(9):1376-82 [16492713.001]
  • [Cites] Eur J Immunol. 1999 Apr;29(4):1253-64 [10229093.001]
  • [Cites] Am J Surg Pathol. 2003 Dec;27(12):1538-45 [14657713.001]
  • [Cites] Leuk Lymphoma. 2006 Jun;47(6):1144-8 [16840208.001]
  • [Cites] Arch Dermatol. 1996 Nov;132(11):1304-8 [8915307.001]
  • (PMID = 20012513.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


19. El-Helw L, Goodwin S, Slater D, Hancock BW: Primary B-cell lymphoma of the skin: the Sheffield Lymphoma Group Experience (1984-2003). Int J Oncol; 2004 Nov;25(5):1453-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary B-cell lymphoma of the skin: the Sheffield Lymphoma Group Experience (1984-2003).
  • The clinical presentation, treatment and outcome were retrospectively evaluated in a series of 66 patients with primary B-cell lymphoma of the skin, referred to the Sheffield lymphoma group (SLG) between 1984 and 2003.
  • The lymphoma database was searched and clinical records were reviewed.
  • Absence of any detectable extracutaneous lesion and the expression of B-cell restricted antigens by neoplastic cells were the essential criteria for selection of cases.
  • The cohort included 37 (56%) males and 29 (44%) females with a mean age of 59 years.
  • The most commonly involved site was the trunk and the disorder typically showed non-aggressive clinical behaviour; the majority of the patients presented with stage I (82%) disease with a tendency to remain localised to a limited area of the skin.
  • Follicular lymphoma was the most common histologic subtype (35%), the next most frequent was the diffuse large cell lymphoma (32%) whereas marginal zone lymphoma constituted 15%.
  • The majority (47%) of patients were treated with radiotherapy for localised disease whereas chemotherapy was given in 20% of patients, with single agent chlorambucil being most frequently used.
  • Surgical excision as the sole modality of treatment was adequate in 33%.
  • DFS was significantly lower with older age (>45 years), leg lesions, generalised and multiple lesions, and for those treated with chemotherapy.
  • Only 7 patients died of lymphoma.
  • In conclusion, primary cutaneous B-cell lymphoma represents a specific entity concerning clinical behaviour, response to treatment, and overall prognosis.
  • [MeSH-major] Lymphoma, B-Cell / pathology. Lymphoma, B-Cell / radiotherapy. Skin Neoplasms / pathology. Skin Neoplasms / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Antigens, Neoplasm / biosynthesis. Databases, Factual. Disease-Free Survival. Female. Great Britain. Humans. Male. Middle Aged. Prognosis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15492838.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, Neoplasm
  •  go-up   go-down


20. Pulini S, Rupoli S, Goteri G, Pimpinelli N, Alterini R, Bettacchi A, Mulattieri S, Picardi P, Tassetti A, Scortechini AR, Fioritoni G, Leoni P: Efficacy and safety of pegylated liposomal doxorubicin in primary cutaneous B-cell lymphomas and comparison with the commonly used therapies. Eur J Haematol; 2009 Mar;82(3):184-93
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and safety of pegylated liposomal doxorubicin in primary cutaneous B-cell lymphomas and comparison with the commonly used therapies.
  • OBJECTIVES: The therapy of advanced, relapsed or refractory primary cutaneous lymphomas is often unsatisfactory.
  • Recent data indicate a favourable pharmacokynetic, pharmacodynamic and toxicity profile of pegylated liposomal doxorubicin (Peg-Doxo) in primary cutaneous T-cell lymphomas, while in primary cutaneous B-cell lymphomas (PCBCLs), the drug efficacy has never been assessed so far.
  • One patient had a marginal zone B-cell lymphoma and four were affected by diffuse large B-cell lymphoma-leg type, all with widespread nodular lesions.
  • RESULTS: All the patients achieved a complete response (CR = 100%) in a short period of time (median 3 months), even when pretreated with radio-chemotherapy.
  • As concerning the toxicity profile, the treatment was well-tolerated, no one decreased or delayed the dose.
  • CONCLUSIONS: In spite of the small number of patients, it emerges that monochemotherapy with Peg-Doxo has a significantly high clinical activity and a good safety profile in PCBCLs, even in aggressive forms, compared with other therapeutic regimens, which are completely reviewed.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Doxorubicin / analogs & derivatives. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / pathology. Polyethylene Glycols / adverse effects. Polyethylene Glycols / therapeutic use. Skin Neoplasms / drug therapy. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Cutaneous B-Cell Lymphomas.
  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19215609.001).
  • [ISSN] 1600-0609
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / liposomal doxorubicin; 30IQX730WE / Polyethylene Glycols; 80168379AG / Doxorubicin
  •  go-up   go-down


21. Gellrich S, Muche JM, Wilks A, Jasch KC, Voit C, Fischer T, Audring H, Sterry W: Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an applicational observation. Br J Dermatol; 2005 Jul;153(1):167-73
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an applicational observation.
  • BACKGROUND: Primary cutaneous B-cell lymphomas (PCBCLs) are characterized by restriction to the skin and a variable but mostly favourable prognosis.
  • Since 1997 the recombinant, chimeric anti-CD20 antibody rituximab has been used in patients suffering from non-Hodgkin's B-cell lymphomas.
  • Different studies have shown that the effectiveness and safety in the treatment of patients with low-grade follicular lymphoma is comparable to or even higher than the standard CHOP chemotherapy.
  • So far it has been unclear whether an extended duration of therapy leads to a benefit for the patients with PCBCL.
  • OBJECTIVES: To evaluate the objective response rate, time to progression, remission quality and histological changes and to compare our data with the literature.
  • PATIENTS/METHODS: Ten patients with PCBCL [eight with follicle centre cell lymphoma (FCCL), one with marginal zone lymphoma (MZL) and one with diffuse large B-cell lymphoma of the leg (DLBCL)] were treated by intravenous application of a chimeric antibody against the CD20 transmembrane antigen (rituximab) with a dosage of eight cycles, 375 mg m(-2) body surface, weekly.
  • RESULTS: The treatment regimen resulted in clinical overall response in 9 of 10 patients, in particular there were seven complete responses (70%) plus two partial responses (20%).
  • In two patients no histology was taken after treatment; one patient developed a new lesion.
  • As expected the B-cell count in peripheral blood was depressed in all patients after infusion.
  • CONCLUSIONS: Intravenous therapy with eight cycles of the anti-CD20 antibody rituximab is a non-toxic and effective treatment for a subset of patients with PCBCL (relapsed, aggressive entity, old patients, multiple lesions) with a long DR.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Lymphoma, B-Cell / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-Derived. Antigens, CD20 / immunology. Disease Progression. Disease-Free Survival. Drug Administration Schedule. Drug Evaluation. Humans. Male. Middle Aged. Rituximab. Treatment Outcome

  • Genetic Alliance. consumer health - Cutaneous B-Cell Lymphomas.
  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16029344.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 28
  •  go-up   go-down


22. Hallermann C, Kaune KM, Tiemann M, Kunze E, Griesinger F, Mitteldorf C, Bertsch HP, Neumann C: High frequency of primary cutaneous lymphomas associated with lymphoproliferative disorders of different lineage. Ann Hematol; 2007 Jul;86(7):509-15

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High frequency of primary cutaneous lymphomas associated with lymphoproliferative disorders of different lineage.
  • In patients suffering from primary cutaneous lymphomas, secondary malignancies of various origin may develop.
  • However, the frequency of a second neoplasm deriving from another lymphoid lineage is still unclear and may be underestimated.
  • We screened all our patients with primary cutaneous lymphomas from a 4-year recruitment period for a coexisting secondary lymphoproliferative disorder.
  • The cohort comprised of a total of 82 patients with primary cutaneous lymphomas, 62 with primary cutaneous T-cell lymphoma (CTCL), 18 with primary cutaneous B-cell lymphomas, and two with CD4+/CD56+ hematodermic neoplasm/blastic lymphomas.
  • Seven patients (8.5%) were identified with a coexisting lymphoma of a different lymphoid lineage.
  • Four patients with Sézary syndrome (SS) suffered from systemic B-cell lymphoma.
  • Two of these developed SS after chemotherapy of their B-cell lymphoma.
  • The other three patients with various types of skin lymphomas (SS, Mycosis fungoides [MF], primary cutaneous marginal zone lymphoma) developed Hodgkin's disease (hairy cell leukemia).
  • Our data indicate that patients with primary cutaneous lymphomas have an elevated risk for the development of a secondary lymphoproliferative disorder even without previous chemotherapy.
  • Possible explanations for this association include a genetic predisposition, alterations in early progenitor cells, underlying viral infections, and/or stimulation of a B-cell clone by the malignant helper T cells of the primary CTCL and vice versa.
  • [MeSH-major] Lymphoma, T-Cell, Cutaneous / complications. Lymphoproliferative Disorders / complications. Neoplasms, Second Primary / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Ann Hematol. 2007 Jul;86(7):517. Kaune, Matthias Kjell [corrected to Kaune, Kjell Matthias]
  • [ErratumIn] Ann Hematol. 2007 Jul;86(7):517
  • (PMID = 17340135.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


23. Kerl K, Prins C, Saurat JH, French LE: Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: report and follow-up of eight cases. Br J Dermatol; 2006 Dec;155(6):1197-200
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: report and follow-up of eight cases.
  • BACKGROUND: Rituximab (MabThera); Roche, Basel, Switzerland; an anti-CD20 chimeric monoclonal antibody) has been shown to have significant activity in nodal B-cell lymphomas, with few associated adverse effects.
  • Its efficacy and safety were first demonstrated in the treatment of systemic B-cell lymphomas.
  • Intravenous and subsequently intralesional administration of rituximab have also been reported to be effective and well tolerated in cutaneous B-cell lymphoma (CBCL).
  • OBJECTIVES: To evaluate the objective response rate, relapse rate, time to progression, and tolerance in patients with CBCL treated with intravenous or intralesional rituximab.
  • METHODS: Eight patients with multiple primary CBCL (four follicle centre lymphoma and four marginal zone lymphoma) were treated with intralesional rituximab (six patients; 10-30 mg per lesion, three times weekly for one or two cycles at a 4-week interval) or intravenous rituximab (two patients; 375 mg m(-2) once weekly for four consecutive weeks).
  • Four of six patients treated intralesionally presented a relapse of new lesions at another site within a mean of 6 months after treatment.
  • Tolerance to treatment was very good in both treatment groups.
  • CONCLUSIONS: Rituximab therapy of CBCL appears to have a potential advantage in cases where lesions are localized in sites that are difficult to treat with radiotherapy or surgery and in which secondary scarring or alopecia is likely.
  • Intralesional injections of rituximab allow the use of considerably smaller doses compared with intravenous treatment, with similar response rates and tolerance.
  • However, within a 12-month follow-up period, relapse of CBCL with new lesions at distinct sites was frequently observed after intralesional treatment.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Agents / administration & dosage. Lymphoma, B-Cell / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Murine-Derived. Female. Humans. Injections, Intralesional. Injections, Intravenous. Male. Middle Aged. Neoplasm Recurrence, Local. Rituximab. Treatment Outcome

  • Genetic Alliance. consumer health - Cutaneous B-Cell Lymphomas.
  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17107389.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


24. Seker M, Ustaalioğlu BB, Bilici A, Yildirim ME, Kefeli U, Barisik NO, Tamer I, Gumus M: Eight-cycle rituximab therapy resulted in complete remission in primary cutaneous marginal zone lymphoma. Leuk Res; 2010 Jul;34(7):e160-3
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Eight-cycle rituximab therapy resulted in complete remission in primary cutaneous marginal zone lymphoma.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Lymphoma, B-Cell, Marginal Zone / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived. Antiviral Agents / therapeutic use. Drug Administration Schedule. Hepatitis B, Chronic / complications. Hepatitis B, Chronic / drug therapy. Humans. Immunophenotyping. Lamivudine / therapeutic use. Male. Remission Induction. Reverse Transcriptase Inhibitors / therapeutic use. Rituximab

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. LAMIVUDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20219245.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Letter; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / Antiviral Agents; 0 / Reverse Transcriptase Inhibitors; 2T8Q726O95 / Lamivudine; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 23
  •  go-up   go-down


25. Mandekou-Lefaki I, Delli FS, Kountouras J, Athanasiou E, Mattheou-Vakali G: Primary cutaneous MALT-type lymphoma and Helicobacter pylori: a possible relationship. J Eur Acad Dermatol Venereol; 2006 May;20(5):606-8
Hazardous Substances Data Bank. Clarithromycin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous MALT-type lymphoma and Helicobacter pylori: a possible relationship.
  • [MeSH-major] Helicobacter Infections / complications. Helicobacter pylori. Lymphoma, B-Cell, Marginal Zone / complications. Skin Neoplasms / complications
  • [MeSH-minor] Adult. Amoxicillin / administration & dosage. Clarithromycin / administration & dosage. Diagnosis, Differential. Drug Therapy, Combination. Female. Humans. Male. Middle Aged. Omeprazole / administration & dosage

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. AMOXICILLIN .
  • Hazardous Substances Data Bank. OMEPRAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Eur Acad Dermatol Venereol. 2008 May;22(5):648-9 [18363682.001]
  • [ErratumIn] J Eur Acad Dermatol Venereol. 2011 Feb;25(2):249. Kountouras, I [corrected to Kountouras, J]
  • (PMID = 16684296.001).
  • [ISSN] 0926-9959
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 804826J2HU / Amoxicillin; H1250JIK0A / Clarithromycin; KG60484QX9 / Omeprazole
  •  go-up   go-down






Advertisement